The Scientific Basis of This Innovation
The result of six years of field, laboratory and technical research: an antivenom designed for the medically important species of Iraq and the Middle East.
Innovation Built on Knowledge
Our proprietary know-how is the starting point for our work. Research conducted in-house and the development of biological innovations tailored to regional needs have formed the basis for our certification as a knowledge-based company.
Research & Development
We conduct in-house research and development of biological products, from antigen design to the final product.
Proprietary Know-How
Our know-how is developed in-house and owned entirely by the company.
Regional Research
Our research and product design are informed by disease patterns in our target countries.
Certified Knowledge-Based Company
Recognized as an innovative knowledge-based company by the Vice-Presidency for Science and Technology, in the field of pharmaceuticals and advanced diagnostic and therapeutic products. Scan the QR code — or tap it — to open the registry.
RasFab®
A heptavalent antivenom designed to neutralize the venom of seven medically important snake species found across Iraq and the Middle East — a proprietary achievement built on a region-specific approach.
The Development Pathway
Field Studies and Venom Profiling
Identifying the medically important species and profiling their venom across the different regions of Iraq.
Research & Development
Translating field findings into a defined scientific and technical framework for the product — antigen selection, formulation strategy and the development of proprietary know-how.
Laboratory Development
Immunization, fractionation and neutralizing-potency studies toward a heptavalent formulation.
Semi-Industrial Scale
Transferring the process developed at laboratory scale to semi-industrial scale, with technical, quality and efficacy assessment against the target species.
Industrial Scale
Manufacturing at industrial scale in line with GMP requirements, with consistent, reproducible quality across batches.
Proprietary Commercialization
Registration in target markets and regional supply, with full ownership of the technology and know-how retained by Wargah Sazan Kimia.
Research & Development Programmes
Focused on developing specialized biological products to meet regional and international therapeutic needs.
Human Tetanus Immunoglobulin (TIG)
Human Tetanus Immunoglobulin (TIG) is under development as one of the company’s biological product research and development programmes. The programme is focused on developing a high-quality human immunoglobulin, using advanced purification technologies and in line with international quality requirements.
- Programme
- Human Tetanus Immunoglobulin (TIG)
- Product Class
- Human Biological Product
- Therapeutic Use
- Passive Immunization
- Development Framework
- Aligned with GMP requirements
- Status
- Research & Development
Sea Snake Antivenom
Development of a proprietary sea snake antivenom, aimed at meeting the treatment needs of coastal regions facing sea snake envenomation. The programme rests on the company’s experience in antivenom development, purification technologies and biological manufacturing.
- Programme
- Sea Snake Antivenom
- Product Class
- Therapeutic Biological Product
- Core Technology
- Equine Immunoglobulin
- Status
- Research & Development
Proprietary Scorpion Antivenom
Alongside the scorpion antivenom already in our product range, a programme to develop a new proprietary antivenom is under way. It is being developed around the medically important species of the Middle East and selected target markets. The field-study phase of this programme is complete and the project has entered research and development.
- Programme
- Proprietary Scorpion Antivenom
- Product Class
- Scorpion Antivenom
- Core Technology
- Equine Immunoglobulin
- Region
- Middle East and selected target markets
- Status
- Field studies completed; in research and development
Achievements of Proprietary Know-How
Meeting Regional Health Needs
Antivenom developed to match the medically important species and epidemiological needs of each region.
Technology Development
A platform for developing new biological products and transferring know-how.
Regional Innovation
A product developed around the real needs and epidemiological conditions of the region.
Frequently Asked Questions About RasFab®
What is RasFab®, and which company developed and manufactures it?
RasFab® is a proprietary heptavalent snake antivenom developed and manufactured by Wargah Sazan Kimia. It is the result of six years of field, laboratory and technical research focused on medically important snake species in Iraq and the wider Middle East.
Why was RasFab® developed as a region-specific antivenom?
Venom composition can vary among populations of the same species across different geographic regions. For this reason, effective antivenom development should reflect the medically important species and epidemiological needs of each target region. RasFab® was developed according to this region-specific scientific approach.
Which medically important snake venoms is RasFab® designed to neutralise?
RasFab® is designed to neutralise the venoms of seven medically important snake species found across Iraq and the wider Middle East:
Walterinnesia morgani · Pseudocerastes fieldi · Cerastes gasperettii · Echis carinatus · Macrovipera lebetina · Montivipera raddei · Pseudocerastes persicus
What scientific work supported the development of RasFab®?
The development of RasFab® was supported by six years of field, laboratory and technical research conducted by Wargah Sazan Kimia. The programme included regional species identification, venom profiling, antigen selection, formulation development, immunisation, fractionation and neutralizing-potency studies, followed by scale-up toward stable, reproducible industrial production.
What regional need was RasFab® developed to address?
RasFab® was developed with a primary focus on the medically important snake species and epidemiological conditions of Iraq. Its heptavalent formulation also reflects broader antivenom needs across the Middle East.